X
All Data
Our shared vision is to have a World, free of Pain.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 16, 2020
Details:
The Phase I trial aims to demonstrate a favourable safety and tolerability profile and to confirm the pharmacokinetic characteristics of an investigational peripherally restricted Nociceptin/orphanin peptide receptor (NOP) agonist following single and multiple-ascending doses.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Anle138b
Therapeutic Area: Neurology Product Name: Anle138b
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 23, 2020
Details:
The short-term Phase 1b study with PD patients will be conducted by Quotient Sciences in e clinical trial initiation of a first-in-patient Phase 1b study for anle138b in patients with mild to moderate Parkinson´s Disease (PD).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Anle138b
Therapeutic Area: Neurology Product Name: Anle138b
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: The Michael J. Fox Foundation for Parkinson's Research.
Deal Size: $1.4 million Upfront Cash: Undisclosed
Deal Type: Funding August 05, 2020
Details:
Anle138b which was administered in doses of up to 300 mg daily, demonstrated excellent safety and tolerability profiles at all dose levels and reached significantly higher plasma levels in humans than those required for full therapeutic efficacy in animal models.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
